Since ADCC is impaired by tumor-induced immunosuppression in breast cancer patients [46], our results pave the way for the development of combined immunotherapies able to further stimulate the activity of NK cells in order to enhance the efficacy of Her2-targeting monoclonal antibodies or vaccines. This evidence concerns the gene ERBB2 and neoplasm.